ZA931906B - Itraconazole and saperconazole sereoisomers - Google Patents

Itraconazole and saperconazole sereoisomers

Info

Publication number: ZA931906B
Authority: ZA; South Africa
Prior art keywords: itraconazole; sereoisomers; saperconazole; pharmaceutically acceptable; stereoisomer
Prior art date: 1992-03-18

Application number

ZA931906A

Other languages

English (en)

Inventor

Jan Heeres

Jean-Louis Mesens

Jozef Peeters

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-18

Filing date

1993-03-17

Publication date

1994-09-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25316567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA931906(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-03-17 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1994-09-17 Publication of ZA931906B publication Critical patent/ZA931906B/xx

Links

VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 title abstract 2
229960004130 itraconazole Drugs 0.000 title abstract 2
HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 title 1
229950005137 saperconazole Drugs 0.000 title 1
206010017533 Fungal infection Diseases 0.000 abstract 1
208000031888 Mycoses Diseases 0.000 abstract 1
230000002924 anti-infective effect Effects 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000009885 systemic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
230000000699 topical effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nanotechnology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Crystallography & Structural Chemistry (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

ZA931906A 1992-03-18 1993-03-17 Itraconazole and saperconazole sereoisomers ZA931906B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US85364892A	1992-03-18	1992-03-18

Publications (1)

Publication Number	Publication Date
ZA931906B true ZA931906B (en)	1994-09-17

Family

ID=25316567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA931906A ZA931906B (en)	1992-03-18	1993-03-17	Itraconazole and saperconazole sereoisomers

Country Status (21)

Country	Link
US (1)	US5998413A (de)
EP (1)	EP0631578B1 (de)
KR (1)	KR100243534B1 (de)
AT (1)	ATE201408T1 (de)
AU (1)	AU665988B2 (de)
CA (1)	CA2117651C (de)
CZ (1)	CZ286619B6 (de)
DE (1)	DE69330248T2 (de)
DK (1)	DK0631578T3 (de)
ES (1)	ES2158859T3 (de)
FI (1)	FI113175B (de)
GR (1)	GR3036368T3 (de)
HU (1)	HU221189B1 (de)
NO (1)	NO307786B1 (de)
NZ (1)	NZ249494A (de)
PL (1)	PL172358B1 (de)
PT (1)	PT631578E (de)
RU (1)	RU2127733C1 (de)
SK (1)	SK283118B6 (de)
WO (1)	WO1993019061A1 (de)
ZA (1)	ZA931906B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08509464A (ja) *	1993-01-27	1996-10-08	セプラコア，インコーポレイテッド	（２ｒ，４ｓ）イトラコナゾールを使用する方法および組成物
PH31594A (en) *	1993-09-30	1998-11-03	Janssen Pharmaceutica Nv	Oral formulations on an antifungal.
TW438601B (en) *	1994-05-18	2001-06-07	Janssen Pharmaceutica Nv	New mucoadhesive emulsion compositions and a process for the preparation thereof
US5486625A (en) *	1994-07-08	1996-01-23	Schering Corporation	Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2112151B1 (es) *	1995-03-17	1999-09-16	Menarini Lab	Nuevos compuestos homoquirales para la preparacion de ketoconazol, terconazol y antifungicos relacionados, procedimiento para su fabricacion y utilizacion de los mismos.
DE69733664T3 (de)	1996-04-19	2011-04-14	Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles	Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
ATE255883T1 (de) *	1996-05-20	2003-12-15	Janssen Pharmaceutica Nv	Fungizide mittel mit verbesserter bioverfügbarkeit
EP0942725A1 (de) *	1996-11-12	1999-09-22	Sepracor, Inc.	Verwendung von cis-hydroxyitraconazole um unerwünschte nebeneffekte von itraconazole und hydroxytraconazole zu vermeiden
JP2001504121A (ja) *	1996-11-12	2001-03-27	セプラコール，インク．	２ｒ，４ｓ，ｒ，ｓ―および２ｓ，４ｒ，ｒ，ｓ―ヒドロキシイトラコナゾール―およびヒドロキシサパーコナゾール誘導体
CN1237174A (zh) *	1996-11-12	1999-12-01	塞普拉科公司	2r,4s,s,r－和2s,4r,s,r－羟基伊曲康唑
WO1998021204A1 (en)	1996-11-12	1998-05-22	Sepracor, Inc.	2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole
AU5251398A (en) *	1996-11-12	1998-06-03	Sepracor, Inc.	(2r,4s,r,r-) and (2s,4r,r,r-)hydroxyitraconazole
WO1998034934A1 (en)	1997-02-11	1998-08-13	Janssen Pharmaceutica N.V.	Amino acid ester containing azole antifungals
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
EP0957101A1 (de) *	1998-05-14	1999-11-17	Janssen Pharmaceutica N.V.	Wasserlösliche Azole als Breitspektrum-antifungus
ES2251985T3 (es)	1999-03-24	2006-05-16	R.P. Scherer Technologies, Inc.	Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion.
KR100331529B1 (ko) *	1999-06-16	2002-04-06	민경윤	난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6932861B2 (en)	2000-11-28	2005-08-23	Fmc Corporation	Edible PGA coating composition
KR100438485B1 (ko) *	2001-08-13	2004-07-09	한국디디에스제약 주식회사	아졸류 항진균제의 약제학적 조성물
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en)	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
US7446107B2 (en) *	2002-02-15	2008-11-04	Transform Pharmaceuticals, Inc.	Crystalline forms of conazoles and methods of making and using the same
WO2004000284A1 (en)	2002-06-21	2003-12-31	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
CA2477923C (en)	2002-03-01	2021-02-23	University Of South Florida	Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1511490A4 (de) *	2002-05-31	2009-03-11	Transform Pharmaceuticals Inc	Neue kristalline conazol-formen und verwandte prozesse, pharmazeutische zusammensetzungen und verfahren
US20070059356A1 (en) *	2002-05-31	2007-03-15	Almarsson Oern	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR100446256B1 (ko) *	2002-07-11	2004-09-01	경동제약 주식회사	고 광학선택성을 가지는시스-2-(브로모메틸)-2-(2,4-디클로로페닐)-13-디옥소란-4-메틸알콜의 제조방법
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
US8486456B2 (en)	2005-08-08	2013-07-16	Abbott Gmbh & Co., Kg	Itraconazole compositions with improved bioavailability
PL1912626T3 (pl)	2005-08-08	2016-10-31		Postaci użytkowe o polepszonej biodostępności
US8653083B2 (en)	2005-08-22	2014-02-18	The Johns Hopkins University	Hedgehog pathway antagonists to treat disease
EP2753179A4 (de) *	2011-09-09	2015-03-04	Univ Leland Stanford Junior	Topische itraconazol-formulierungen und ihre verwendung
CN102379844A (zh) *	2011-10-31	2012-03-21	广州维美投资有限公司	一种伊曲康唑异构体注射剂
CN105061411A (zh) *	2015-06-23	2015-11-18	扬州艾迪生物科技有限公司	一种光学异构体2s,4r,2’s-伊曲康唑晶型及制备方法与应用
CN106146480B (zh) *	2016-07-18	2019-08-06	山东罗欣药业集团恒欣药业有限公司	一种伊曲康唑的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4267179A (en) *	1978-06-23	1981-05-12	Janssen Pharmaceutica, N.V.	Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4287195A (en) *	1978-07-14	1981-09-01	Janssen Pharmaceutica, N.V.	Heterocyclic derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4490530A (en) *	1981-01-14	1984-12-25	Janssen Pharmaceutica N.V.	Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles
HU191101B (en) *	1983-02-14	1987-01-28	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu	Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3346123A1 (de) *	1983-12-21	1985-06-27	Janssen Pharmaceutica, N.V., Beerse	Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) *	1985-03-15	1985-04-17	Janssen Pharmaceutica Nv	Derivatives of y-cyclodextrin
US4916134A (en) *	1987-03-25	1990-04-10	Janssen Pharmacuetica N.V.	4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
FR2622198B1 (fr) *	1987-10-21	1992-04-30	Mero Rousselot Satia	Compositions granulees de polysaccharides a dissolution aqueuse instantanee, procede pour leur preparation et utilisation
US5002935A (en) *	1987-12-30	1991-03-26	University Of Florida	Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) *	1987-12-30	1991-05-21	University Of Florida	Redox systems for brain-targeted drug delivery
HK1009335A1 (en) *	1989-04-03	1999-05-28	Janssen Pharmaceutica N.V.	Regioselective substitutions in cyclodextrins
GB8908250D0 (en) *	1989-04-12	1989-05-24	Fisons Plc	Formulations
US5214046A (en) *	1989-07-27	1993-05-25	Hoffmann-La Roche Inc.	Substituted aminoalkoxybenzene anti-fungicidal compositions and use
JPH08509464A (ja) *	1993-01-27	1996-10-08	セプラコア，インコーポレイテッド	（２ｒ，４ｓ）イトラコナゾールを使用する方法および組成物

1993
- 1993-03-10 CA CA002117651A patent/CA2117651C/en not_active Expired - Fee Related
- 1993-03-10 WO PCT/EP1993/000552 patent/WO1993019061A1/en not_active Ceased
- 1993-03-10 SK SK1106-94A patent/SK283118B6/sk unknown
- 1993-03-10 DE DE69330248T patent/DE69330248T2/de not_active Expired - Fee Related
- 1993-03-10 CZ CZ19942215A patent/CZ286619B6/cs not_active IP Right Cessation
- 1993-03-10 KR KR1019940702921A patent/KR100243534B1/ko not_active Expired - Fee Related
- 1993-03-10 PT PT93905338T patent/PT631578E/pt unknown
- 1993-03-10 DK DK93905338T patent/DK0631578T3/da active
- 1993-03-10 HU HU9402656A patent/HU221189B1/hu not_active IP Right Cessation
- 1993-03-10 AU AU36324/93A patent/AU665988B2/en not_active Ceased
- 1993-03-10 RU RU94045798A patent/RU2127733C1/ru not_active IP Right Cessation
- 1993-03-10 EP EP93905338A patent/EP0631578B1/de not_active Expired - Lifetime
- 1993-03-10 NZ NZ249494A patent/NZ249494A/en not_active IP Right Cessation
- 1993-03-10 ES ES93905338T patent/ES2158859T3/es not_active Expired - Lifetime
- 1993-03-10 PL PL93305223A patent/PL172358B1/pl not_active IP Right Cessation
- 1993-03-10 AT AT93905338T patent/ATE201408T1/de not_active IP Right Cessation
- 1993-03-17 ZA ZA931906A patent/ZA931906B/xx unknown
1994
- 1994-09-16 FI FI944311A patent/FI113175B/fi active
- 1994-09-16 NO NO943450A patent/NO307786B1/no unknown
1996
- 1996-07-09 US US08/676,531 patent/US5998413A/en not_active Expired - Fee Related
2001
- 2001-08-10 GR GR20010401224T patent/GR3036368T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
PL172358B1 (en)	1997-09-30
WO1993019061A1 (en)	1993-09-30
DE69330248T2 (de)	2002-03-21
NO943450D0 (no)	1994-09-16
ES2158859T3 (es)	2001-09-16
SK110694A3 (en)	1995-04-12
HUT71835A (en)	1996-02-28
RU94045798A (ru)	1996-07-20
HK1010729A1 (en)	1999-06-25
NO943450L (no)	1994-11-11
GR3036368T3 (en)	2001-11-30
KR950700904A (ko)	1995-02-20
KR100243534B1 (ko)	2000-03-02
CZ286619B6 (cs)	2000-05-17
NZ249494A (en)	1996-04-26
HU221189B1 (en)	2002-08-28
FI944311A0 (fi)	1994-09-16
US5998413A (en)	1999-12-07
HU9402656D0 (en)	1994-11-28
CA2117651A1 (en)	1993-09-30
FI113175B (fi)	2004-03-15
NO307786B1 (no)	2000-05-29
CZ221594A3 (en)	1995-01-18
DE69330248D1 (de)	2001-06-28
CA2117651C (en)	2006-01-03
PT631578E (pt)	2001-11-30
RU2127733C1 (ru)	1999-03-20
AU3632493A (en)	1993-10-21
DK0631578T3 (da)	2001-08-27
FI944311L (fi)	1994-09-16
SK283118B6 (sk)	2003-02-04
AU665988B2 (en)	1996-01-25
EP0631578A1 (de)	1995-01-04
ATE201408T1 (de)	2001-06-15
EP0631578B1 (de)	2001-05-23

Publication	Publication Date	Title
ZA931906B (en)	1994-09-17	Itraconazole and saperconazole sereoisomers
CA2426703A1 (en)	2002-05-30	Therapeutic agents and methods of use thereof for the modulation of angiogenesis
MX9505182A (es)	1997-02-28	Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
CA2095223A1 (en)	1992-05-17	Topical compositions for transdermal delivery of prodrug derivatives of morphine
HUP9601566A2 (en)	1997-09-29	Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
CA2277824A1 (en)	1998-07-16	Dosage composition for nasal delivery and method of use of the same
CA2125662A1 (en)	1993-07-08	Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
MY118526A (en)	2004-11-30	Method for improving the pharmacokinetics of tipranavir
GR3015014T3 (en)	1995-05-31	Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts.
EP0663835A1 (de)	1995-07-26	Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft.
MX9504023A (es)	1997-05-31	Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
RU94041028A (ru)	1996-09-20	Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
GB9509888D0 (en)	1995-07-12	Terpenoidic derivatives useful as antitumour agents
AU1656997A (en)	1997-10-02	Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
AU1898792A (en)	1994-01-04	Treatment or therapeutic booth for energetic, cosmetic and medical purposes
CA2218643A1 (en)	1996-12-12	Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
RU94040865A (ru)	1996-08-10	Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
IL110511A0 (en)	1994-10-21	Topical pharmaceutical formulation for treating viral infections
NZ328198A (en)	2000-04-28	a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor
CA2135752A1 (en)	1993-12-09	Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
UA41326C2 (uk)	2001-09-17	Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
HUP9801596A3 (en)	2000-07-28	Use of azole compounds for preparing pharmaceutical compositions useful for the treatment of fungal infections, new azole derivatives and pharmaceutical compositions containing them
EP1712231A3 (de)	2007-11-21	Methode zur Verbesserung der Pharmakokinetik von Tipranavir
ITMI931205A0 (it)	1993-06-08	Composizione farmaceutica per l'applicazione topica di 17b estradiolo nel trattamento della cheratocongiuntivite sicca
ZA929143B (en)	1993-08-16	Agents for use in the prophylaxis and therapy of fungal infections.